ADReCS

Pharmaceutical Information

Drug Name	Testosterone cypionate
Drug ID	BADD_D02171
Description	Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Indications and Usage	Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153]
Marketing Status	approved
ATC Code	Not Available
DrugBank ID	DB13943
KEGG ID	D00957
MeSH ID	C016131
PubChem ID	441404
TTD Drug ID	Not Available
NDC Product Code	60870-0252; 64025-0021; 0009-0086; 0143-9726; 52536-625; 62756-016; 0409-6562; 70700-288; 46439-8736; 62991-3132; 48087-0096; 0143-9659; 69097-536; 69097-802; 70700-289; 0574-0827; 76420-065; 51927-0189; 73774-016; 0591-4128; 38779-0164; 46204-0371; 60722-3016; 47781-911; 62756-015; 69097-537; 0143-9005; 63629-8706; 70700-290; 71225-127; 0009-0027; 47781-910; 63187-647; 63629-8705; 0517-1830; 51927-2706; 65089-0049; 73301-010; 0009-0347; 49803-006; 51552-0104; 63275-9982; 82393-114; 62756-017; 0409-6557; 0574-0820; 71205-289; 22552-0010; 43647-678; 0009-0085; 0009-0417; 50090-4147
UNII	M0XW1UBI14
Synonyms	testosterone 17 beta-cypionate \| testosterone cypionate \| testosterone 17 beta-cyclopentanepropionate \| testosterone 17 beta-cyclopentylpropionate \| Depo-Testosterone \| Depo-Testosterone Cypionate \| deposteron \| Duratest \| Testa-C \| Testex Elmu \| Andronate \| Depostomead

Chemical Information

Molecular Formula	C27H40O3
CAS Registry Number	58-20-8
SMILES	CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hemiplegia	17.01.04.002	0.002621%		Not Available
Hepatic neoplasm	16.07.03.001; 09.04.03.001	-	-	Not Available
Hirsutism	23.02.04.001; 05.05.01.005	-	-
Hypersensitivity	10.01.03.003	0.011742%
Hypersomnia	19.02.05.001; 17.15.01.001	0.001048%
Hypertension	24.08.02.001	0.008597%
Incontinence	20.02.02.004; 17.05.01.006; 07.01.06.011	0.001048%		Not Available
Injection site bruising	23.03.11.015; 12.07.03.042; 08.02.03.042; 24.07.06.017	0.009436%		Not Available
Injection site erythema	23.03.06.015; 12.07.03.001; 08.02.03.001	0.012267%		Not Available
Injection site induration	12.07.03.007; 08.02.03.007	0.004089%		Not Available
Injection site inflammation	12.07.03.009; 08.02.03.008	0.002831%		Not Available
Injection site irritation	12.07.03.027; 08.02.03.027	0.003565%		Not Available
Injection site mass	12.07.03.010; 08.02.03.009	0.013000%		Not Available
Injection site pain	12.07.03.011; 08.02.03.010	0.065527%		Not Available
Injection site pruritus	23.03.12.007; 12.07.03.014; 08.02.03.013	0.006395%		Not Available
Injection site rash	12.07.03.032; 08.02.03.032; 23.03.13.010	0.003565%		Not Available
Injection site reaction	12.07.03.015; 08.02.03.014	0.010694%
Injection site warmth	12.07.03.036; 08.02.03.036	0.004089%		Not Available
Intracranial pressure increased	17.07.02.002	0.001573%		Not Available
Jaundice cholestatic	09.01.01.005	-	-	Not Available
Lacrimation increased	06.08.02.004	0.003565%
Lethargy	19.04.04.004; 17.02.04.003; 08.01.01.008	0.004089%
Libido decreased	19.08.03.001; 21.03.02.005	0.004089%
Libido increased	21.03.02.007; 19.08.03.002	-	-
Lip swelling	23.04.01.007; 10.01.05.005; 07.05.04.005	0.004089%		Not Available
Liver function test abnormal	13.03.04.030	-	-	Not Available
Loss of libido	19.08.03.003	0.002097%		Not Available
Lung disorder	22.02.07.001	0.002097%		Not Available
Lymphadenopathy	01.09.01.002	0.003565%		Not Available
Memory impairment	19.20.01.003; 17.03.02.003	0.004718%

The 3th Page First Pre 3 4 5 6 Next Last Total 6 Pages